Company intelligence / Profile preview

Watkins-Conti Products

Edmond, Oklahoma, United Stateswatkinscontiproducts.com ↗

Ownership: Private
Development stage: NDA

Overview

Watkins Conti’s flagship product Yōni.Fit® demonstrated efficacy and safety for the temporary management of urine leakage caused by stress urinary incontinence (SUI) in women. The device was evaluated through a randomized controlled clinical trial published in Urogynecology and received FDA 510(k) clearance in 2024. It offers a non-surgical option for SUI management and can be prescribed via telehealth or office visit. Covered by most major insurance plans

Therapeutic areas: Women's Health
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Yōni.Fit

Commercial

Indications: Stress urinary incontinence

Partnerships

Edgepark (Cardinal Health business unit – distribution partner)

Beyond the preview

Go deeper on Watkins-Conti Products.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Watkins-Conti Products.

Explore the full profile